Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | AQP1 | P29972 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.32 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.32 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596852 | 0.89 | HTR2A (0.46) | HTR2AHTR2CAQP1CHRM1PRKAB2 | |
| SCHEMBL4596590 | 0.84 | HTR1A (0.38) | HTR2AHTR2CAQP1CHRM1CHRM3 | |
| SCHEMBL4596508 | 0.83 | PRKAB2 (0.39) | HTR2APRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4711150 | 0.83 | GPBAR1 (0.36) | HTR2APRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4596566 | 0.81 | AQP1 (0.41) | HTR2AHTR2CAQP1USP7 | |
| SCHEMBL4713782 | 0.81 | AQP1 (0.37) | HTR2AHTR2CAQP1USP7 | |
| SCHEMBL4220557 | 0.81 | AQP1 (0.56) | HTR2AHTR2CAQP1CHRM1CHRM3 | |
| SCHEMBL4597300 | 0.81 | KDM4E (0.37) | — | |
| SCHEMBL4221743 | 0.80 | AQP1 (0.46) | HTR2AHTR2CAQP1CHRM1CHRM3 | |
| SCHEMBL4712016 | 0.80 | AQP1 (0.40) | HTR2AHTR2CAQP1USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879569-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | Wyeth (US) | 2008-01-23 | — | — | EP | claimed |
| EP-1874292-A2 | METHODS FOR MODULATING BLADDER FUNCTION | Wyeth (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1871356-A1 | DIHYDROBENZOFURAN DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | claimed |
| EP-1871355-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | Wyeth (US) | 2008-01-02 | — | — | EP | claimed |
| JP-2007509174-A | — | — | 2007-04-12 | — | — | JP | claimed |
| WO-2006116221-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116170-A1 | DIHYDROBENZOFURAN DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116149-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116169-A2 | METHODS FOR MODULATING BLADDER FUNCTION | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | claimed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | claimed |
| EP-1998764-A2 | METHODS FOR TREATING COGNITIVE AND OTHER DISORDERS | Wyeth a Corporation of the State of Delaware (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1898895-A2 | TREATMENT OF DRUG ABUSE | Wyeth (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1879569-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | Wyeth (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006116221-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006116148-A2 | (7-ARLYSUBSTITUTED 2, 3-DIHYDR0-1-BENZ0FURAN-2-YL) ALKYLAMINES IN THE TREATMENT' OF SUBSTANCE ABUSE | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | HTR2A 11/4885HTR2C 1/4885AQP1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.